Novel oral anticoagulants (NOACs) have been developed as alternatives for vitamin K antagonists (VKAs) for
the prevention of thromboembolic events in patients with a variety of medical conditions. In this review, we summarize
the current data on NOACs safety and efficacy compared to VKAs and in specific patients’ groups including heart valve
replacement, venous thromboembolism, advanced renal failure and the elderly.